Folkman remembered as creative, kind

This afternoon, I spoke with Harold Dvorak, a colleague of Judah Folkman's at Harvard, who reacted to his colleague's linkurl:sudden passing;http://www.the-scientist.com/blog/display/54173/ yesterday. He said that he's spent the day thinking back over Folkman's generosity as a physician, not only his achievements as a pioneer in anti-angiogenesis therapy for cancer. Hundreds of patients contacted Folkman with problems - an incurable case of cancer, for instance - and he stayed i

Written byAlison McCook
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share
This afternoon, I spoke with Harold Dvorak, a colleague of Judah Folkman's at Harvard, who reacted to his colleague's linkurl:sudden passing;http://www.the-scientist.com/blog/display/54173/ yesterday. He said that he's spent the day thinking back over Folkman's generosity as a physician, not only his achievements as a pioneer in anti-angiogenesis therapy for cancer. Hundreds of patients contacted Folkman with problems - an incurable case of cancer, for instance - and he stayed in touch with them, Dvorak said, adding that he hears "all the time" about patients who reached out to Folkman and received a personal response. "I don't know if he ever slept," what with running a large lab and keeping in contact with so many patients. "I've never known anybody quite like him," he added. Another one of Folkman's defining qualities was his ability to come up with novel ideas, Dvorak added. "He wasn't always right, but that's part of the risk of being novel," he said. "You'd never hear a talk by him without coming away with some new idea." He added: "Judah Folkman was one of the most creative men I've ever met. And one of the most creative scientists I've ever met." "Judah Folkman's passing is a tremendous and tragic loss for humankind," AACR Chief Executive Officer Margaret Foti said in a statement. "His legacy of discovery and ingenuity in the field of angiogenesis will continue to inspire cancer researchers and give hope to countless individuals living with the disease. He was certainly a valued friend of the AACR and we extend our deepest condolences to the Folkman family."
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies